The Sputnik V coronavirus vaccine developed in Russia showed a 91.6% effectiveness rate in the phase 3 trial, Reuters reported Tuesday, citing data published by The Lancet.
The publication further showed that there were no serious adverse events associated with the vaccine, which was equally effective in people older than 60 years.
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
